{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:53:11Z","timestamp":1780987991092,"version":"3.54.1"},"reference-count":11,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,29]]},"DOI":"10.1182\/blood.2023023108","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T17:08:38Z","timestamp":1709226518000},"page":"741-742","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Toward a cure for cHL without chemotherapy"],"prefix":"10.1182","volume":"143","author":[{"given":"Ryan C.","family":"Lynch","sequence":"first","affiliation":[{"name":"University of Washington and Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2024022917082957500_bib1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy in older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"key":"2024022917082957500_bib2","doi-asserted-by":"crossref","first-page":"725219","DOI":"10.1155\/2011\/725219","article-title":"Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States","volume":"2011","author":"Shenoy","year":"2011","journal-title":"Adv Hematol"},{"issue":"1","key":"2024022917082957500_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"2024022917082957500_bib4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"30","key":"2024022917082957500_bib5","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"17_suppl","key":"2024022917082957500_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024022917082957500_bib7","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"},{"key":"2024022917082957500_bib8","article-title":"Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients","author":"Ghesquieres","year":"18  2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024022917082957500_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood-2023-180114","article-title":"Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged \u226560 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826","volume":"140","author":"Rutherford","year":"2023","journal-title":"Blood"},{"key":"2024022917082957500_bib10","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","author":"Alig","year":"11  2023","journal-title":"Nature"},{"issue":"21","key":"2024022917082957500_bib11","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/9\/741\/2216659\/blood_bld-2023-023108-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/9\/741\/2216659\/blood_bld-2023-023108-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T17:08:45Z","timestamp":1709226525000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/9\/741\/515061\/Toward-a-cure-for-cHL-without-chemotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,2,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023108","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}